Shares of Oncothyreon rose on 10 December following the announcement that its partner Merck had started a late-stage study on Stimuvas as a potential lung cancer treatment.

The Phase III trial, named Inspire, will focus on Asian patients with advanced non-small cell lung cancer.

It will enroll about 420 patients in China, Hong Kong, South Korea, Singapore and Taiwan.